Peptides

"Research use only": what that label actually means for peptides in the US

By the US Health Digest editorial team · Published August 30, 2026 · Every claim linked to its primary source

"Research use only" is not an FDA approval category, an exemption, or a safety standard. The exact phrase appears in one place in FDA's regulations — 21 CFR 809.10(c)(2)(i), a labelling rule for in vitro diagnostic products, meaning laboratory test kits, not injectable drugs. FDA's guidance on that label says "[m]ere placement of an RUO or IUO label on an IVD product does not render the device exempt from otherwise applicable clearance, approval, or other requirements." For drugs, intended use governs: under 21 U.S.C. § 321(g)(1), an article intended to affect the structure or function of the body is a drug, whatever the vial says. FDA has told peptide sellers so in writing as recently as June 17, 2026.

Where the label comes from

The phrase has a legal home. Section 809.10(c) exempts certain shipments of in vitro diagnostic products from ordinary labelling requirements, and (c)(2)(i) sets the condition: "For a product in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product, all labeling bears the statement, prominently placed: 'For Research Use Only. Not for use in diagnostic procedures.'" FDA's guidance of November 25, 2013 agrees: "An RUO product is an IVD product that is in the laboratory research phase of development and is being shipped or delivered for an investigation that is not subject to part 812."

A full-text search of FDA's regulations for that phrase on August 30, 2026 returned section 809.10 and nothing else. Two things follow. The category is about diagnostic test kits under development — a lyophilised peptide sold to be reconstituted and injected is not one. And even inside its own domain the label is not a shield: the guidance adds that "FDA may determine that the device is intended for use in clinical diagnosis based on other evidence, including how the device is marketed."

There is a drug-side analogue, and it reads nothing like a retail disclaimer. 21 CFR 312.160 lets a person ship an unapproved drug intended solely for tests in vitro or in laboratory animals if it is labelled "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans." It also imposes a duty most sellers never mention: the shipper "shall use due diligence to assure that the consignee is regularly engaged in conducting such tests," and must keep records of who received it. A tickbox at checkout is not that.

Why "not for human consumption" appears at all

Because intended use decides the category. Under 21 U.S.C. § 321(g)(1), "drug" includes "articles (other than food) intended to affect the structure or any function of the body of man or other animals." 21 CFR 201.128 defines intended use as "the objective intent of the persons legally responsible for the labeling of an article," which "may, for example, be shown by labeling claims, advertising matter, or oral or written statements." The disclaimer is aimed at the seller's exposure. It is one piece of evidence about intent, weighed against everything else on the site — and in the letters below, it loses.

The five legal boxes

Nothing about a molecule's size or sequence fixes its legal status; the route it travels to a buyer does — and the same word covers several separate markets. A product sits in exactly one of these boxes.

One further status matters because vendors invoke it. Under FDA's interim compounding policy, nominated bulk substances were sorted into three categories. For Category 1, FDA "does not intend to take action against a compounder… provided that the conditions described in the guidance document are met"; Category 2 holds substances for which FDA "has identified significant safety risks." Neither is a list of legal ingredients. That list is 21 CFR 216.23(a), with six entries.

What enforcement has looked like

Not hypothetical, and not confined to GLP-1 copies. FDA's letters follow a template built around the disclaimer.

• Prime Vitality, Inc. dba Prime Peptides, December 10, 2024: despite labelling for "research purposes only" and "not for human consumption or clinical use," FDA wrote, "evidence obtained from your website establishes that your products are intended to be drugs for human use."
• Warrior Labz SARMS, June 12, 2023, which names TB-500 among the unapproved new drugs the firm marketed.
• Gram Peptides and Prime Sciences, both March 31, 2026 — the latter over products labelled for "laboratory research purposes only" and "not for human consumption, medical use or veterinary use."
• Wholesale Peptide, June 17, 2026 — products labelled "RESEARCH USE ONLY" and "not for human consumption," held to violate "sections 301(d) and 505(a) of the FD&C Act."

That last date matters: it is three months after the shift vendors describe as making peptides legal again.

The "peptides are legal again" claim, checked against the record

Pages ranking for peptide-legality queries are largely vendor-run, and several assert that roughly fourteen peptides were moved from Category 2 back to Category 1 in 2026, restoring a legal route to buy them, and attribute that change to an announcement by Health and Human Services Secretary Robert F. Kennedy Jr. Here is the entire federal paper trail we could find.

The removals happened, but not for the stated reason, and not to Category 1. FDA's list of nominated bulk substances, updated May 14, 2026, records one addition to Category 1: "GHK-Cu (except for injectable routes of administration)." FDA explains that GHK-Cu "was removed from category 1 on April 22, 2026, because the nominations for GHK-Cu were withdrawn by the nominators," that on May 5, 2026 one of those nominators "clarified that it intended to withdraw only its nomination of the injectable route of administration," and that the non-injectable entry "will be added back to category 1." That is one substance, restored in part because a nominator amended its own paperwork — and FDA adds that it "intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list." That 503A list contains no BPC-157, TB-500, KPV, MOTS-C, CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604, selank, semax or epitalon in any of its three categories. FDA's companion page says the same of the peptides that left Category 2: "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators."

A withdrawn nomination is not a reclassification. It means the party who asked FDA to list the substance stopped asking, and it drops the substance out of the categorisation scheme entirely — including out of the Category 1 posture in which FDA says it does not intend to act against compounders. It satisfies nothing in section 503A, which requires a USP or NF monograph, status as a component of an approved drug, or a place on the 503A bulks list. That list, at 21 CFR 216.23(a) on August 27, 2026, is six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. Adding to it requires notice-and-comment rulemaking; a Federal Register search on August 30, 2026 found none since the 2019 final rule.

The advisory meeting is real; it is also advisory. FDA published a notice on April 16, 2026 scheduling the Pharmacy Compounding Advisory Committee for July 23–24, 2026 to discuss BPC-157, KPV, TB-500, MOTS-C, emideltide, semax and epitalon. Advisory committee recommendations are non-binding in any event, and FDA's meeting page still carried no minutes, transcript or vote record when we checked on August 30, 2026 — only briefing documents, agendas and rosters. No rule followed. Our BPC-157 report covers what FDA's own reviewers concluded beforehand.

The one rulemaking-track action of 2026 ran the other way. A notice FDA announced on April 30 and published on May 1, 2026 proposes to keep three peptide drugs off the 503B bulks list: "FDA tentatively finds no basis to conclude that there is a clinical need for an outsourcing facility to compound using the following bulk drug substances: semaglutide, tirzepatide, and liraglutide." The comment period, extended on June 26, closed July 30, 2026; no final determination had been published as of August 30, 2026. A proposal, not a permanent exclusion — but the opposite of liberalisation.

What we could not find. Searching HHS's press room, FDA's newsroom, the Federal Register by term and by docket, and FDA's compounding pages turned up no HHS or FDA document announcing a peptide reclassification to Category 1. We make no claim here about what the Secretary said or did not say: we could obtain no primary record of any such statement, so we report only what the documents show. The vendor framing compresses a nominator's paperwork withdrawal and a non-binding advisory committee meeting into a legal change no document performs — while FDA was still sending warning letters in June.

What independent testing finds

The published record here is small: no study we found has systematically tested retail vials of the popular research peptides. What exists is adjacent and consistent. A 2024 study in the Journal of Medical Internet Research made test purchases of semaglutide from illegal online sellers: the three vials delivered contained 28.56% to 38.69% more drug than labelled, endotoxin in every sample, and measured purity of 7.7% to 14.37% against a claimed 99%. A 2020 analysis co-authored by United States Pharmacopeia scientists found 20% and 43% by weight of undeclared mannitol in two commercially sourced research peptides. A June 2026 review in Cureus names the structural problem as "products of uncertain identity, purity, potency, sterility, and safety." A vendor's certificate of analysis is not evidence against any of that — our guide to certificates of analysis explains why.

Seller exposure, buyer exposure

These are different, and conflating them is how both panic and complacency get sold. What follows describes federal food-and-drug law; it is not legal advice, and state law differs.

The seller. 21 U.S.C. § 331 prohibits introducing or delivering for introduction into interstate commerce a misbranded drug (§ 331(a)) or any article in violation of § 355 (§ 331(d)). Section 333(a)(1) makes a violation punishable by up to a year's imprisonment; § 333(a)(2) raises that to three years for a repeat violation or one committed "with the intent to defraud or mislead."

The buyer. The prohibited-act list is written around commerce, not consumption. Section 331(c) reaches "[t]he receipt in interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise" — receipt paired with passing it on. Simple possession of an unapproved drug is not among the prohibited acts; "possession" appears in § 331 only in connection with counterfeiting equipment and colored oleomargarine. One conspicuous exception: § 333(e) makes it an offence punishable by up to five years to knowingly distribute "or possess[] with intent to distribute, human growth hormone" — "somatrem, somatropin, or an analogue of either of them" — outside an authorised medical use.

Importing. FDA's Regulatory Procedures Manual, chapter 9 (version 05, March 2024) sets out the personal-importation policy at subchapter 9-2, and it is enforcement discretion, not permission. FDA personnel may allow entry when quantity and purpose are clearly personal and the product poses no unreasonable risk, but the manual adds: "Although FDA may use discretion to allow admission of certain violative items, this should not be interpreted as a license to individuals to bring in such shipments." One of the two more permissive routes it describes — the one for an unapproved use in a serious condition — requires, among other things, that "there is no known commercialization or promotion to persons residing in the U.S. by those involved in the distribution of the product," and that the importer affirm in writing that it is for personal use, "generally not more than 3 month supply," naming a US-licensed treating physician. A peptide promoted to US consumers by a US-facing site fails the first of those.

Questions to ask before buying anything labelled "research use only"

• Which of the five categories above is it in? If the seller cannot name one, the answer is the fifth.
• If it is genuinely research material, is it labelled under 21 CFR 312.160, and did the shipper use "due diligence" to establish that I am "regularly engaged in conducting such tests"?
• Does the same site that disclaims human use carry dosing charts, before-and-after images or condition claims? Under 21 CFR 201.128, that is evidence of intended use.
• If a compounded product is offered instead: which pharmacy or outsourcing facility, and is the bulk substance on 21 CFR 216.23(a), in a USP/NF monograph, or a component of an approved drug? "Removed from Category 2" answers none of those.
• Is anyone saying a 2026 announcement made this legal? Ask which Federal Register document, which docket, which rule.
• For an injectable: who tested this lot for identity, potency, sterility and endotoxin, and is that laboratory named and independently accredited?

We publish no doses, vendors or sourcing for any unapproved peptide.

Sources

1. 21 CFR 809.10(c)(2)(i) — labelling condition for in vitro diagnostic products in the laboratory research phase of development: "For Research Use Only. Not for use in diagnostic procedures." Text as of August 27, 2026 (eCFR). Link.
2. FDA. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only — Guidance for Industry and FDA Staff, issued November 25, 2013 (CDRH/CBER) — "Mere placement of an RUO or IUO label…" and the definition of an RUO product. Link.
3. 21 CFR 312.160 — drugs for investigational use in laboratory research animals or in vitro tests; required caution statement and the shipper's due-diligence and recordkeeping duties. Link.
4. 21 CFR 201.128 — meaning of "intended uses"; objective intent shown by labelling claims, advertising matter, or statements. Link.
5. 21 U.S.C. § 321 — definitions of "drug" (§ 321(g)(1)) and "dietary supplement" (§ 321(ff)), including the exclusion at § 321(ff)(3)(B)(ii) (via Legal Information Institute, Cornell Law School). Link.
6. 21 U.S.C. § 355(a) — no new drug may be introduced or delivered for introduction into interstate commerce without an effective approved application. Link.
7. 21 U.S.C. § 331 — prohibited acts, including § 331(a), (c) and (d). Link.
8. 21 U.S.C. § 333 — penalties: § 333(a)(1) and (a)(2), and the human growth hormone offence at § 333(e). Link.
9. 21 CFR 216.23 — the 503A bulks list; six listed substances at paragraph (a), the evaluation criteria at (c), and the misbranding provision at (d). Text as of August 27, 2026 (eCFR). Link.
10. 21 CFR 600.3(h)(6) — "A protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." Link.
11. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — category lists, updated May 14, 2026; the sole Category 1 addition is "GHK-Cu (except for injectable routes of administration)," which had been removed on April 22, 2026 "because the nominations for GHK-Cu were withdrawn by the nominators" and is being added back after a nominator clarified on May 5, 2026 that it meant to withdraw only the injectable route. Link.
12. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — definitions of categories 1, 2 and 3 and FDA's stated enforcement intention for each; page content current as of May 14, 2026. Link.
13. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators"; page content current as of April 22, 2026. Link.
14. Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting … Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List, 91 FR 20465, April 16, 2026, Docket No. FDA–2025–N–6895 — the July 23–24, 2026 agenda and the section 503A conditions. Link; PDF via govinfo.
15. FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — event materials; no minutes, transcript or vote record posted as of August 30, 2026. Link.
16. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act, Notice, 91 FR 23431, May 1, 2026, Docket No. FDA–2018–N–3240 — FDA's tentative finding and proposal not to include semaglutide, tirzepatide and liraglutide. Link; PDF via govinfo.
17. Federal Register. Same notice; Extension of Comment Period, June 26, 2026 — comments extended until July 30, 2026. Link.
18. FDA. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, press announcement, April 30, 2026. Link.
19. Federal Register. List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A, final rule, 84 FR 4696, February 19, 2019 — the rulemaking that created 21 CFR 216.23. Link.
20. FDA. Warning letter to Prime Vitality, Inc. dba Prime Peptides, 695156, December 10, 2024. Link.
21. FDA. Warning letter to Wholesale Peptide, 729447, June 17, 2026. Link.
22. FDA. Warning letter to Prime Sciences, 721805, March 31, 2026. Link. Warning letter to Gram Peptides, 721806, March 31, 2026. Link.
23. FDA. Warning letter to Warrior Labz SARMS, 655280, June 12, 2023 — names TB-500 among the unapproved new drugs the firm marketed. Link. Warning letter to GenoGenix LLC, 718739, January 20, 2026 — thymosin beta-4 as an unapproved new drug and a biological product. Link.
24. FDA. Regulatory Procedures Manual, Chapter 9: Import Operations and Actions, MAN-000012, version 05, March 2024 — subchapter 9-2, Coverage of Personal Importations. Link.
25. Ashraf AR, Mackey TK, Vida RG, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription. J Med Internet Res. November 7, 2024. PMID 39509151.
26. Choules MP, Bisson J, Simmler C, et al. NMR reveals an undeclared constituent in custom synthetic peptides. J Pharm Biomed Anal. January 2020 — 20% and 43% w/w undeclared mannitol. PMID 31671336.
27. Hailu KT, Abriha FN, Duguma YM, et al. Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks. Cureus. June 11, 2026 — narrative review. PMID 42437212.